O	O	O	0	23	Dimethyldithiocarbamate	Dimethyldithiocarbamate	B-NP	NN	O	2	SUB	O
O	O	O	24	32	inhibits	inhibit	B-VP	VBZ	O	0	ROOT	O
O	O	O	33	35	in	in	B-NP	FW	O	4	AMOD	O
O	O	O	36	41	vitro	vitro	I-NP	FW	O	5	NMOD	O
O	O	O	42	52	activation	activation	I-NP	NN	O	2	OBJ	O
O	O	O	53	55	of	of	B-PP	IN	O	5	NMOD	O
O	O	O	56	63	primary	primary	B-NP	JJ	B-cell_type	12	NMOD	B-cell_type
O	O	O	64	69	human	human	I-NP	JJ	I-cell_type	12	NMOD	I-cell_type
T1	B-Protein	B-Protein	70	73	CD4	CD4	I-NP	NN	I-cell_type	12	NMOD	I-cell_type
O	O	O	73	74	+	+	B-NP	SYM	I-cell_type	12	NMOD	I-cell_type
O	O	O	75	76	T	T	I-NP	NN	I-cell_type	12	NMOD	I-cell_type
O	O	O	77	88	lymphocytes	lymphocyte	I-NP	NNS	I-cell_type	6	PMOD	I-cell_type
O	O	O	88	89	.	.	O	.	O	2	P	O

O	O	O	91	107	Dithiocarbamates	Dithiocarbamate	B-NP	NNS	O	8	NMOD	O
O	O	O	108	109	(	(	O	(	O	4	DEP	O
O	O	O	109	112	DTC	DTC	B-NP	NN	O	4	DEP	O
O	O	O	112	113	)	)	O	)	O	1	NMOD	O
O	O	O	113	114	,	,	O	,	O	8	P	O
O	O	O	115	116	a	a	B-NP	DT	O	8	NMOD	O
O	O	O	117	124	diverse	diverse	I-NP	JJ	O	8	NMOD	O
O	O	O	125	130	group	group	I-NP	NN	O	15	SUB	O
O	O	O	131	133	of	of	B-PP	IN	O	8	NMOD	O
O	O	O	134	144	industrial	industrial	B-NP	JJ	O	12	AMOD	O
O	O	O	145	148	and	and	I-NP	CC	O	12	AMOD	O
O	O	O	149	160	therapeutic	therapeutic	I-NP	JJ	O	13	NMOD	O
O	O	O	161	170	chemicals	chemical	I-NP	NNS	O	9	PMOD	O
O	O	O	170	171	,	,	O	,	O	8	P	O
O	O	O	172	176	have	have	B-VP	VBP	O	0	ROOT	O
O	O	O	177	181	been	be	I-VP	VBN	O	15	VC	O
O	O	O	182	190	reported	report	I-VP	VBN	O	16	VC	O
O	O	O	191	193	to	to	I-VP	TO	O	19	VMOD	O
O	O	O	194	201	inhibit	inhibit	I-VP	VB	O	17	VMOD	O
O	O	O	201	202	,	,	I-VP	,	O	19	P	O
O	O	O	203	210	enhance	enhance	I-VP	VB	O	19	VMOD	O
O	O	O	211	213	or	or	I-VP	CC	O	19	VMOD	O
O	O	O	214	218	have	have	I-VP	VB	O	19	VMOD	O
O	O	O	219	221	no	no	B-NP	DT	O	25	NMOD	O
O	O	O	222	228	effect	effect	I-NP	NN	O	19	VMOD	O
O	O	O	229	231	on	on	B-PP	IN	O	25	NMOD	O
O	O	O	232	235	the	the	B-NP	DT	O	29	NMOD	O
O	O	O	236	242	immune	immune	I-NP	JJ	O	29	NMOD	O
O	O	O	243	249	system	system	I-NP	NN	O	26	PMOD	O
O	O	O	249	250	.	.	O	.	O	15	P	O

O	O	O	251	256	These	These	B-NP	DT	O	3	NMOD	O
O	O	O	257	265	apparent	apparent	I-NP	JJ	O	3	NMOD	O
O	O	O	266	281	inconsistencies	inconsistency	I-NP	NNS	O	4	SUB	O
O	O	O	282	289	reflect	reflect	B-VP	VBP	O	0	ROOT	O
O	O	O	290	293	the	the	B-NP	DT	O	6	NMOD	O
O	O	O	294	304	complexity	complexity	I-NP	NN	O	4	OBJ	O
O	O	O	305	307	of	of	B-PP	IN	O	6	NMOD	O
O	O	O	308	311	the	the	B-NP	DT	O	11	NMOD	O
O	O	O	312	316	DTCs	DTC	I-NP	NNS	O	11	NMOD	O
O	O	O	317	327	biological	biological	B-NP	JJ	O	11	NMOD	O
O	O	O	328	338	activities	activity	I-NP	NNS	O	7	PMOD	O
O	O	O	339	342	and	and	O	CC	O	4	VMOD	O
O	O	O	343	346	are	be	B-VP	VBP	O	4	VMOD	O
O	O	O	347	355	probably	probably	B-ADVP	RB	O	13	VMOD	O
O	O	O	356	359	due	due	B-ADJP	JJ	O	18	PMOD	O
O	O	O	360	362	in	in	B-PP	IN	O	18	PMOD	O
O	O	O	363	367	part	part	B-NP	NN	O	16	PMOD	O
O	O	O	368	370	to	to	B-PP	TO	O	13	PRD	O
O	O	O	371	382	differences	difference	B-NP	NNS	O	18	PMOD	O
O	O	O	383	385	in	in	B-PP	IN	O	19	NMOD	O
O	O	O	386	390	dose	dose	B-NP	NN	O	31	NMOD	O
O	O	O	390	391	,	,	O	,	O	31	P	O
O	O	O	392	397	route	route	B-NP	NN	O	31	NMOD	O
O	O	O	398	400	of	of	B-PP	IN	O	23	NMOD	O
O	O	O	401	409	exposure	exposure	B-NP	NN	O	24	PMOD	O
O	O	O	409	410	,	,	O	,	O	31	P	O
O	O	O	411	417	animal	animal	B-NP	NN	O	28	NMOD	O
O	O	O	418	425	species	specie	I-NP	NNS	O	31	NMOD	O
O	O	O	426	430	used	use	B-VP	VBN	O	28	NMOD	O
O	O	O	431	434	and	and	O	CC	O	31	NMOD	O
O	O	O	434	435	/	/	B-NP	SYM	O	34	NMOD	O
O	O	O	435	437	or	or	O	CC	O	34	NMOD	O
O	O	O	438	446	specific	specific	B-NP	JJ	O	34	NMOD	O
O	O	O	447	455	compound	compound	I-NP	NN	O	20	PMOD	O
O	O	O	456	462	tested	test	B-VP	VBN	O	34	NMOD	O
O	O	O	462	463	.	.	O	.	O	4	P	O

O	O	O	464	467	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	468	475	studies	study	I-NP	NNS	O	5	SUB	O
O	O	O	476	485	described	describe	B-VP	VBN	O	2	NMOD	O
O	O	O	486	492	herein	herein	B-ADVP	RB	O	3	VMOD	O
O	O	O	493	497	were	be	B-VP	VBD	O	0	ROOT	O
O	O	O	498	508	undertaken	undertake	I-VP	VBN	O	5	VC	O
O	O	O	509	511	to	to	I-VP	TO	O	8	VMOD	O
O	O	O	512	523	investigate	investigate	I-VP	VB	O	6	VMOD	O
O	O	O	524	527	the	the	B-NP	DT	O	10	NMOD	O
O	O	O	528	542	immunotoxicity	immunotoxicity	I-NP	NN	O	8	OBJ	O
O	O	O	543	545	of	of	B-PP	IN	O	10	NMOD	O
O	O	O	546	549	one	one	B-NP	CD	O	13	NMOD	O
O	O	O	550	556	member	member	I-NP	NN	O	18	NMOD	O
O	O	O	557	559	of	of	B-PP	IN	O	13	NMOD	O
O	O	O	560	564	this	this	B-NP	DT	O	16	NMOD	O
O	O	O	565	571	family	family	I-NP	NN	O	14	PMOD	O
O	O	O	571	572	,	,	O	,	O	18	P	O
O	O	O	573	596	dimethyldithiocarbamate	dimethyldithiocarbamate	B-NP	NN	O	11	PMOD	O
O	O	O	597	598	(	(	O	(	O	21	DEP	O
O	O	O	598	603	DMDTC	DMDTC	B-NP	NN	O	21	DEP	O
O	O	O	603	604	)	)	O	)	O	18	NMOD	O
O	O	O	604	605	.	.	O	.	O	5	P	O

O	O	O	606	608	We	We	B-NP	PRP	O	2	SUB	O
O	O	O	609	620	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	621	625	that	that	B-SBAR	IN	O	2	VMOD	O
O	O	O	626	627	0	0	B-NP	CD	O	8	AMOD	O
O	O	O	627	628	.	.	O	.	O	4	P	O
O	O	O	628	629	1	1	B-NP	CD	O	8	AMOD	O
O	O	O	629	630	-	-	I-NP	HYPH	O	8	P	O
O	O	O	630	631	0	0	I-NP	CD	O	12	NMOD	O
O	O	O	631	632	.	.	I-NP	.	O	12	NMOD	O
O	O	O	632	633	5	5	I-NP	CD	O	11	AMOD	O
O	O	O	634	640	microM	microM	I-NP	NN	O	12	NMOD	O
O	O	O	641	646	DMDTC	DMDTC	I-NP	NN	O	13	SUB	O
O	O	O	647	655	inhibits	inhibit	B-VP	VBZ	O	3	SBAR	O
T2	B-Protein	B-Protein	656	659	TNF	TNF	B-NP	NN	B-protein	13	OBJ	B-protein
T2	I-Protein	I-Protein	659	660	-	-	B-ADJP	HYPH	O	16	P	O
T2	I-Protein	I-Protein	660	665	alpha	alpha	B-PP	SYM	O	14	NMOD	O
O	O	O	665	666	-	-	I-PP	HYPH	O	16	PMOD	O
O	O	O	666	673	induced	induce	B-NP	VBN	O	19	NMOD	O
O	O	O	674	684	activation	activation	I-NP	NN	O	17	PMOD	O
O	O	O	685	687	of	of	B-PP	IN	O	19	NMOD	O
T7	B-Entity	B-Entity	688	690	NF	NF	B-NP	NN	B-protein	23	NMOD	B-protein
T7	I-Entity	I-Entity	690	691	-	-	O	HYPH	I-protein	23	NMOD	I-protein
T7	I-Entity	I-Entity	691	697	kappaB	kappaB	B-NP	NN	I-protein	20	PMOD	I-protein
O	O	O	698	700	in	in	B-PP	IN	O	19	NMOD	O
O	O	O	701	708	primary	primary	B-NP	JJ	B-cell_type	30	NMOD	B-cell_type
O	O	O	709	714	human	human	I-NP	JJ	I-cell_type	30	NMOD	I-cell_type
T3	B-Protein	B-Protein	715	718	CD4	CD4	I-NP	NN	I-cell_type	30	NMOD	I-cell_type
O	O	O	718	719	+	+	I-NP	SYM	I-cell_type	30	NMOD	I-cell_type
O	O	O	720	721	T	T	I-NP	NN	I-cell_type	30	NMOD	I-cell_type
O	O	O	722	727	cells	cell	I-NP	NNS	I-cell_type	24	PMOD	I-cell_type
O	O	O	727	728	.	.	O	.	O	2	P	O

O	O	O	729	733	This	This	B-NP	DT	O	2	NMOD	O
O	O	O	734	744	inhibition	inhibition	I-NP	NN	O	3	SUB	O
O	O	O	745	747	is	be	B-VP	VBZ	O	18	VMOD	O
O	O	O	748	751	not	not	I-VP	RB	O	3	VMOD	O
O	O	O	752	763	accompanied	accompany	I-VP	VBN	O	3	VC	O
O	O	O	764	766	by	by	B-PP	IN	O	5	VMOD	O
O	O	O	767	768	a	a	B-NP	DT	O	8	NMOD	O
O	O	O	769	773	loss	loss	I-NP	NN	O	6	PMOD	O
O	O	O	774	776	in	in	B-PP	IN	O	8	NMOD	O
O	O	O	777	786	viability	viability	B-NP	NN	O	9	PMOD	O
O	O	O	786	787	,	,	O	,	O	18	P	O
O	O	O	788	791	and	and	O	CC	O	18	VMOD	O
O	O	O	792	797	DMDTC	DMDTC	B-NP	NN	O	17	NMOD	O
O	O	O	797	798	-	-	B-NP	HYPH	O	17	NMOD	O
O	O	O	798	805	treated	treat	I-NP	VBN	O	17	NMOD	O
O	O	O	806	807	T	T	I-NP	NN	B-cell_type	17	NMOD	B-cell_type
O	O	O	808	813	cells	cell	I-NP	NNS	I-cell_type	18	SUB	I-cell_type
O	O	O	814	820	retain	retain	B-VP	VBP	O	0	ROOT	O
O	O	O	821	826	other	other	B-NP	JJ	O	22	NMOD	O
O	O	O	827	833	active	active	I-NP	JJ	O	22	NMOD	O
O	O	O	834	843	signaling	signaling	I-NP	NN	O	22	NMOD	O
O	O	O	844	852	pathways	pathway	I-NP	NNS	O	18	OBJ	O
O	O	O	853	863	throughout	throughout	B-PP	IN	O	18	VMOD	O
O	O	O	864	867	the	the	B-NP	DT	O	26	NMOD	O
O	O	O	868	876	exposure	exposure	I-NP	NN	O	26	NMOD	O
O	O	O	877	885	duration	duration	I-NP	NN	O	23	PMOD	O
O	O	O	885	886	.	.	O	.	O	18	P	O

O	O	O	887	890	The	The	B-NP	DT	O	2	NMOD	O
O	O	O	891	901	inhibition	inhibition	I-NP	NN	O	7	SUB	O
O	O	O	902	904	of	of	B-PP	IN	O	2	NMOD	O
T8	B-Entity	B-Entity	905	907	NF	NF	B-NP	NN	B-protein	6	NMOD	B-protein
T8	I-Entity	I-Entity	907	908	-	-	B-NP	HYPH	I-protein	6	NMOD	I-protein
T8	I-Entity	I-Entity	908	914	kappaB	kappaB	I-NP	NN	I-protein	3	PMOD	I-protein
O	O	O	915	917	is	be	B-VP	VBZ	O	0	ROOT	O
O	O	O	918	928	apparently	apparently	B-ADJP	RB	O	7	VMOD	O
O	O	O	929	938	permanent	permanent	I-ADJP	JJ	O	7	PRD	O
O	O	O	939	941	as	as	B-PP	IN	O	7	VMOD	O
O	O	O	942	947	DMDTC	DMDTC	B-NP	NN	O	15	NMOD	O
O	O	O	947	948	-	-	B-NP	HYPH	O	15	NMOD	O
O	O	O	948	955	treated	treat	I-NP	VBN	O	15	NMOD	O
O	O	O	956	957	T	T	I-NP	NN	B-cell_type	15	NMOD	B-cell_type
O	O	O	958	963	cells	cell	I-NP	NNS	I-cell_type	10	PMOD	I-cell_type
O	O	O	964	967	did	do	B-VP	VBD	O	7	VMOD	O
O	O	O	968	971	not	not	I-VP	RB	O	16	VMOD	O
O	O	O	972	978	regain	regain	I-VP	VB	O	16	VC	O
O	O	O	979	985	normal	normal	B-NP	JJ	O	23	NMOD	O
T4	B-Protein	B-Protein	986	989	TNF	TNF	I-NP	NN	B-protein	23	NMOD	B-protein
T4	I-Protein	I-Protein	989	990	-	-	O	HYPH	O	23	NMOD	O
T4	I-Protein	I-Protein	990	995	alpha	alpha	O	SYM	O	23	NMOD	O
O	O	O	996	1006	activation	activation	B-NP	NN	O	18	OBJ	O
O	O	O	1006	1007	,	,	O	,	O	7	P	O
O	O	O	1008	1012	even	even	B-SBAR	RB	O	26	PMOD	O
O	O	O	1013	1018	after	after	I-SBAR	IN	O	7	VMOD	O
O	O	O	1019	1021	72	72	B-NP	CD	O	28	NMOD	O
O	O	O	1022	1023	h	h	I-NP	NN	O	26	PMOD	O
O	O	O	1024	1026	in	in	B-PP	IN	O	28	NMOD	O
O	O	O	1027	1034	culture	culture	B-NP	NN	O	29	PMOD	O
O	O	O	1034	1035	.	.	O	.	O	7	P	O

O	O	O	1036	1041	DMDTC	DMDTC	B-NP	NN	O	2	SUB	O
O	O	O	1042	1046	does	do	B-VP	VBZ	O	0	ROOT	O
O	O	O	1047	1050	not	not	I-VP	RB	O	2	VMOD	O
O	O	O	1051	1057	appear	appear	I-VP	VB	O	2	VC	O
O	O	O	1058	1060	to	to	I-VP	TO	O	6	VMOD	O
O	O	O	1061	1066	alter	alter	I-VP	VB	O	4	VMOD	O
T9	B-Entity	B-Entity	1067	1069	NF	NF	B-NP	NN	B-protein	9	NMOD	B-protein
T9	I-Entity	I-Entity	1069	1070	-	-	B-NP	HYPH	I-protein	9	NMOD	I-protein
T9	I-Entity	I-Entity	1070	1076	kappaB	kappaB	I-NP	NN	I-protein	6	OBJ	I-protein
O	O	O	1077	1085	directly	directly	B-ADVP	RB	O	6	VMOD	O
O	O	O	1086	1088	as	as	B-PP	IN	O	6	VMOD	O
O	O	O	1089	1092	pre	pre	B-NP	AFX	B-DNA	20	VMOD	B-DNA
O	O	O	1092	1093	-	-	I-NP	HYPH	O	20	P	O
O	O	O	1093	1103	incubation	incubation	B-NP	NN	O	20	SUB	O
O	O	O	1104	1106	of	of	B-PP	IN	O	14	NMOD	O
O	O	O	1107	1114	nuclear	nuclear	B-NP	JJ	O	17	NMOD	O
O	O	O	1115	1123	extracts	extract	I-NP	NNS	O	15	PMOD	O
O	O	O	1124	1128	with	with	B-PP	IN	O	14	NMOD	O
O	O	O	1129	1134	DMDTC	DMDTC	B-NP	NN	O	18	PMOD	O
O	O	O	1135	1139	does	do	B-VP	VBZ	O	11	SBAR	O
O	O	O	1140	1143	not	not	I-VP	RB	O	20	VMOD	O
O	O	O	1144	1152	diminish	diminish	I-VP	VB	O	20	VC	O
O	O	O	1153	1160	binding	binding	B-NP	NN	O	24	NMOD	O
O	O	O	1161	1169	activity	activity	I-NP	NN	O	22	OBJ	O
O	O	O	1170	1172	of	of	B-PP	IN	O	24	NMOD	O
O	O	O	1173	1177	this	this	B-NP	DT	O	27	NMOD	O
O	O	O	1178	1185	protein	protein	I-NP	NN	O	25	PMOD	O
O	O	O	1185	1186	.	.	O	.	O	2	P	O

O	O	O	1187	1189	We	We	B-NP	PRP	O	3	SUB	O
O	O	O	1190	1197	further	further	B-ADVP	RB	O	3	VMOD	O
O	O	O	1198	1209	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	1210	1214	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1215	1216	0	0	B-NP	CD	O	9	AMOD	O
O	O	O	1216	1217	.	.	O	.	O	5	P	O
O	O	O	1217	1218	1	1	B-NP	CD	O	9	AMOD	O
O	O	O	1218	1219	-	-	I-NP	HYPH	O	9	P	O
O	O	O	1219	1220	0	0	I-NP	CD	O	13	NMOD	O
O	O	O	1220	1221	.	.	I-NP	.	O	13	NMOD	O
O	O	O	1221	1222	5	5	I-NP	CD	O	12	AMOD	O
O	O	O	1223	1229	microM	microM	I-NP	NN	O	13	NMOD	O
O	O	O	1230	1235	DMDTC	DMDTC	I-NP	NN	O	14	SUB	O
O	O	O	1236	1244	inhibits	inhibit	B-VP	VBZ	O	4	SBAR	O
O	O	O	1245	1258	intracellular	intracellular	B-NP	JJ	O	19	NMOD	O
T5	B-Protein	B-Protein	1259	1261	IL	IL	I-NP	NN	B-protein	19	NMOD	B-protein
T5	I-Protein	I-Protein	1261	1262	-	-	O	HYPH	I-protein	19	NMOD	I-protein
T5	I-Protein	I-Protein	1262	1263	2	2	B-NP	CD	I-protein	19	NMOD	I-protein
O	O	O	1264	1274	production	production	I-NP	NN	O	14	OBJ	O
O	O	O	1275	1278	and	and	O	CC	O	14	VMOD	O
O	O	O	1279	1288	decreases	decrease	B-VP	VBZ	O	14	VMOD	O
O	O	O	1289	1296	surface	surface	B-NP	NN	O	23	NMOD	O
O	O	O	1297	1307	expression	expression	I-NP	NN	O	21	OBJ	O
O	O	O	1308	1310	of	of	B-PP	IN	O	23	NMOD	O
T6	B-Protein	B-Protein	1311	1315	CD25	CD25	B-NP	NN	B-protein	24	PMOD	B-protein
O	O	O	1316	1317	(	(	O	(	O	36	DEP	O
O	O	O	1317	1320	the	the	B-NP	DT	O	29	NMOD	O
O	O	O	1321	1326	alpha	alpha	I-NP	NN	B-protein	29	NMOD	B-protein
O	O	O	1327	1334	subunit	subunit	I-NP	NN	I-protein	36	DEP	I-protein
O	O	O	1335	1337	of	of	B-PP	IN	O	29	NMOD	O
O	O	O	1338	1341	the	the	B-NP	DT	O	35	NMOD	O
O	O	O	1342	1344	IL	IL	I-NP	NN	B-protein	35	NMOD	B-protein
O	O	O	1344	1345	-	-	B-NP	HYPH	I-protein	35	P	I-protein
O	O	O	1345	1346	2	2	I-NP	CD	I-protein	35	NMOD	I-protein
O	O	O	1347	1355	receptor	receptor	I-NP	NN	I-protein	30	PMOD	I-protein
O	O	O	1355	1356	)	)	O	)	O	25	NMOD	O
O	O	O	1357	1359	in	in	B-PP	IN	O	23	NMOD	O
O	O	O	1360	1361	T	T	B-NP	NN	B-cell_type	39	NMOD	B-cell_type
O	O	O	1362	1367	cells	cell	I-NP	NNS	I-cell_type	37	PMOD	I-cell_type
O	O	O	1368	1378	stimulated	stimulate	B-VP	VBN	O	39	NMOD	O
O	O	O	1379	1383	with	with	B-PP	IN	O	40	VMOD	O
O	O	O	1384	1391	phorbol	phorbol	B-NP	NN	O	43	NMOD	O
O	O	O	1392	1397	ester	ester	I-NP	NN	O	41	PMOD	O
O	O	O	1397	1398	.	.	O	.	O	3	P	O

O	O	O	1399	1404	These	These	B-NP	DT	O	2	NMOD	O
O	O	O	1405	1409	data	datum	I-NP	NNS	O	3	SUB	O
O	O	O	1410	1421	demonstrate	demonstrate	B-VP	VBP	O	0	ROOT	O
O	O	O	1422	1426	that	that	B-SBAR	IN	O	3	VMOD	O
O	O	O	1427	1432	DMDTC	DMDTC	B-NP	NN	O	6	SUB	O
O	O	O	1433	1435	is	be	B-VP	VBZ	O	4	SBAR	O
O	O	O	1436	1437	a	a	B-NP	DT	O	10	NMOD	O
O	O	O	1438	1444	potent	potent	I-NP	JJ	O	10	NMOD	O
O	O	O	1445	1462	immunosuppressive	immunosuppressive	I-NP	JJ	O	10	NMOD	O
O	O	O	1463	1471	compound	compound	I-NP	NN	O	6	PRD	O
O	O	O	1472	1474	in	in	B-ADVP	FW	O	6	VMOD	O
O	O	O	1475	1480	vitro	vitro	I-ADVP	FW	O	11	AMOD	O
O	O	O	1480	1481	.	.	O	.	O	3	P	O
